Mitsubishi UFJ Trust & Banking’s Travere Therapeutics TVTX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$426K	Buy	+7,490	New	+$332K	﹤0.01%	1115

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's TVTX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 7,490 shares worth $426K. The stake represents ﹤0.01% of the portfolio and ranks #1115 among its holdings.

321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 7,490 shares of Travere Therapeutics worth $426K as of Q2 2026.
Travere Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1115 holding.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.